David Grinblatt to Myelodysplastic Syndromes
This is a "connection" page, showing publications David Grinblatt has written about Myelodysplastic Syndromes.
Connection Strength
1.266
-
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015 Apr; 56(4):887-95.
Score: 0.389
-
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
Score: 0.263
-
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. 2023 07; 29(7):460.e1-460.e9.
Score: 0.177
-
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol. 2021 Jun; 43(3):426-432.
Score: 0.150
-
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 02; 23(2):159-170.
Score: 0.122
-
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 08 19; 16:652.
Score: 0.112
-
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
Score: 0.052